Endometrial Cancer

>

Latest News

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.
Frontline Durvalumab Combo Improves PFS/DOR in Advanced Endometrial Cancer

March 19th 2024

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Data from the phase 3 LEAP-001 study support lenvatinib plus pembrolizumab as an active combination for endometrial cancer.
Lenvatinib Combo Prolongs OS, PFS in Advanced Endometrial Cancer Subgroups

March 19th 2024

Retrospective Data Show Real-World Disparities in Black vs White Patients With Endometrioid Endometrial Carcinoma
Retrospective Data Show Real-World Disparities in Black vs White Patients With Endometrioid Endometrial Carcinoma

March 18th 2024

Dostarlimab/Chemo Significantly Improves OS in Advanced Endometrial Cancer
Dostarlimab/Chemo Significantly Improves OS in Advanced Endometrial Cancer

March 16th 2024

Pembrolizumab Combo Yields Survival Benefit in Endometrial Cancer
Pembrolizumab Combo Yields Survival Benefit in Endometrial Cancer

March 16th 2024

Video Series
Video Interviews
Podcasts

More News